ArticleFrontiers in medicine2025
Oxaliplatin combined with capecitabine therapy and comprehensive nursing in advanced colorectal cancer patients.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to discuss the influence of oxaliplatin combined with capecitabine therapy and comprehensive nursing in advanced colorectal cancer (CRC) patients. Methods: A total of 100 advanced CRC patients, selected from January 2019 to January 2021, were divided into a control group (CG) and a research group (RG). Patients in the CG received capecitabine tablets and underwent routine nursing, while those in the RG received capecitabine tablets along with intravenous infusion of oxaliplatin and underwent comprehensive nursing. The short-term effects, levels of tumor markers, immune function, quality of life, occurrence of adverse reactions, negative emotions, and long-term survival rate in both groups were compared. Results: In comparison to the CG, the RG exhibited a higher total effective rate ( Conclusion: Oxaliplatin combined with capecitabine therapy, with comprehensive nursing, can effectively reduce clinical symptoms, enhance the immune function, and improve the quality of life of advanced CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.